Product Description
Mechanisms of Action: RIG1 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Russia | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Institute of Occupational Hygiene and Poison Control, Chinese Center for Disease Control and Prevention/Beijing Zhongcheng Jianxin Investment Services Co., Ltd.
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Silicosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20221117 |
CTR20221117 | P1 |
Completed |
Silicosis |
2006-12-31 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20221121 |
CTR20221121 | P1 |
Completed |
Silicosis |
2006-12-31 |
2025-04-29 |
Patient Enrollment|Treatments |